Navigation Links
MAP Pharmaceuticals to Present Data on LEVADEX® at the 15th Congress of the International Headache Society
Date:6/23/2011

MOUNTAIN VIEW, Calif., June 23, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that LEVADEX® orally inhaled migraine drug will be featured in four poster presentations, including one late-breaker presentation, at the 15th Congress of the International Headache Society (IHC) in Berlin, Germany on June 23-26, 2011. LEVADEX is an investigational drug for migraine and the Company has submitted a New Drug Application to the U.S. Food and Drug Administration for the potential acute treatment of migraine in adults. 

The posters will be presented on Friday, June 24, 4:00-5:00 p.m. CET during Poster Shift 1:

A Long-Term Open-Label Study Assessing the Safety and Tolerability of LEVADEX Orally Inhaled Dihydroergotamine in Adult Migraineurs: In this study, LEVADEX was well-tolerated for the acute treatment of migraine, and did not appear to be associated with any unique safety risk from the inhaled mode of administration.

Abstract #: Late breaking 648

A Thorough QT Study Comparing Supratherapeutic Dose of Orally Inhaled DHE, Moxifloxacin, and Placebo on the QT Interval in Healthy Volunteers: A supratherapeutic dose of orally inhaled DHE, three times the intended clinical LEVADEX dose, did not prolong QTc intervals.

Abstract #: A-345-0001-00565

A Drug Interaction Study Assessing the Effects of CYP3A4 Inhibition on the Pharmacokinetics of LEVADEX (MAP0004, Orally Inhaled DHE) in Healthy Volunteers: Co-administration of LEVADEX with a potent CYP3A4 inhibitor showed no effects on the plasma levels of DHE or its elimination. Therefore, the potential for potent CYP3A4 inhibitors to enhance or prolong the pharmacological effects of orally inhaled DHE appears to be minimal.

Abstract #: A-345-0001-00611

Assessment of the Consistency of Pharmacokinetic Parameters of LEVAD
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... CHESTERBROOK, Pa. , May 24, 2013  Auxilium ... that executive management will participate in the Deutsche Bank ... the Westin Boston Waterfront Hotel.  Mr. Adrian ... scheduled to present an overview of the Company and ... May 29, 2013.   (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ...
(Date:5/24/2013)... , May 24, 2013 ... administration for systemic delivery of therapeutic agents has been ... inhalation drug delivery showing significant promise. The crucial formulation ... a delivery device play a major role in the ... made in the development of new formulation techniques and ...
(Date:5/23/2013)... 23, 2013  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... the 2013 Life Science Firm of the Year by the ... was honored at the TCM,s 25 th Annual Tech ... The Tech Awards Celebration recognizes the leaders and innovators in ... and the surrounding regions. "We ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2
... large, randomized Phase III study of ERBITUX ... neck cancer,meets primary endpoint of improving overall ... /PRNewswire-FirstCall/ -- ImClone,Systems Incorporated and Bristol-Myers Squibb ... III study of ERBITUX(R) (Cetuximab),combined with platinum-based ...
... --,SuperGen Inc. announced today that it will have ... Meeting on April 14-18 in Los Angeles. These ... current oncology,programs including its lead tyrosine kinase inhibitor ... key protein target involved,in cancer cell drug resistance. ...
Cached Medicine Technology:Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 2Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 3Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 4Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 5Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 6Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 7Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 8Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 9SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR 2SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR 3SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR 4
(Date:5/24/2013)... 2013 Gift Card Network members ... in sustainable card material, are combining forces to ... as a sustainable gift card substrate. , The ... challenges and increase education and usage of these ... the reduction of carbon footprint and environmental impact ...
(Date:5/24/2013)... Area homeowners dreaming about owning a hot ... to choose from at factory-direct pricing during the Jacuzzi ... takes place at Emerald Pool and Patio in ... the industry's leading hot tub brand, scheduled the event as ... event will feature popular hot tub models at up to ...
(Date:5/24/2013)... Dwell Media LLC announces the ... Vice President of Digital for Dwell Media. At Yahoo, ... large portion of Yahoo's global media business. At Dwell, ... fully-integrated commerce unit to launch in 2014. Huff brings ... for leading firms in Silicon Valley. Dwell, which has ...
(Date:5/24/2013)... 2013 6Webs.com has educated thousands of ... home security monitoring provider. The easy to ... useful resource consumers prefer for unbiased and impartial home ... of the leading wireless home security system providers in ... on a number of key factors including reliability, technology ...
(Date:5/24/2013)... New York, New York (PRWEB) May 24, 2013 ... 101 Mobility® is a leading nationwide ... accessibility solutions for both consumer and commercial applications. ... ramps, vertical platform lifts, vehicle lifts for mobility ... elevators, among others. 101 Mobility operates over 30 ...
Breaking Medicine News(10 mins):Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 3Health News:Truckload of Jacuzzi® Hot Tubs Rolls into Bend, Oregon on May 24, 2013 for Sales Event 2Health News:Yahoo Commerce Head Joins Leadership at Dwell Media 2Health News:2013 Best Wireless Security System Providers Reported by 6Webs.com 2Health News:Cortec Closes Equity Transaction with 101 Mobility 2
... In the first ever threadbare genetic study of Alzheimer’s, reports ... 79% of the cases, is genetically linked. // ... to it. The disease is marked by apparent confusion, memory ... a place in the Archives of General Psychiatry,However genes cannot ...
... has been an increase in heart failure cases among the elderly, ... men surviving for longer periods. There has been a 14% increase ... period when compared to the 1970 to 1974 period, in the ... ,The chances of heart failure occurring among people ...
... produced by Roche Pharmaceuticals, has been approved by the ... prevention drug in children’s between the ages of 1 ... leading healthcare company situated in Switzerland and are manufacturers ... to be an effective influenza virus drug, which inhibits ...
... leaders, particularly in South Asia to prohibit smoking among the ... the British Medical Journal (BMJ). The help of the Muslim ... ,The researchers analyzed data on the prevalence of smoking ... Smoking rates in each of these countries is significantly higher ...
... who suffer from eating disorders do not reveal it to anyone ... six months. As many as 1,000 youngsters were studied, and the ... of recognizing such disorders in their children, while only 21% of ... ,The research was conducted by the Eating Disorders Association ...
... charges cost so dear, that cancer patients, ill afford ... Charity Breast Cancer Care, 42% of breast cancer patients, ... financial incapacity to afford the prescription charges. Out of ... 15% said they were forced to discontinue the treatment ...
Cached Medicine News:Health News:Eating Disorders Among Children Are Widespread 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: